1 ml of an aqueous solution contains – a concentrate of cerebrolysin (a complex of peptides obtained from the brain of a pig, the molecular weight of which does not exceed 10,000 daltons) 215.2 mg
Cerebrolysin 5 ml, 5 ampoules per pack. 5 or 10 ampoules, together with the attached instructions for medical use, are placed in a cardboard box.
A clear amber solution, free from mechanical impurities.
– Alzheimer’s disease, dementia syndrome of various origins
– ischemic stroke, acute and rehabilitation phase
– traumatic injuries of the brain and spinal cord
– encephalopathy of various origins
– chronic cerebrovascular pathology
– mental retardation in children
– Attention deficit disorders in children
– with psychoorganic syndrome and endogenous depression resistant to antidepressants (as part of complex therapy)
Cerebrolysin 1 ml, 10 ampoules per pack
Cerebrolysin 5 ml, 5 ampoules per pack
Cerebrolysin 10 ml, 5 ampoules per pack
5 or 10 ampoules, together with the attached instructions for medical use, are placed in a cardboard box.
To date, there have been no cases of overdose or intoxication.
Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate the blood-brain barrier and directly enter the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.
Metabolic regulation: Cerebrolysin increases the efficiency of aerobic energy metabolism in the brain, improves intracellular protein synthesis in the developing and aging brain.
Neuroprotection: Cerebrolysin protects neurons from the damaging effects of lactic acidosis, prevents the formation of free radicals, increases survival, and prevents neuronal death under conditions of hypoxia and ischemia, reduces the damaging neurotoxic effect of excitatory amino acids (glutamate).
Neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity, manifested under conditions of peripheral administration and similar to the action of natural neuronal growth factors (NGF).
Functional neuromodulation: Cerebrolysin has a positive effect on impaired cognitive functions, on the processes of memorizing and reproducing information, activates the process of mental activity, improves mood, contributes to the formation of positive emotions, thus exerting a modeling effect on behavior.
The simultaneous use of antidepressants or monoamine oxidase inhibitors in combination with cerebrolysin may increase their action.
Cerebrolysin and balanced amino acid solutions should not be mixed in the same solution for infusion.
Cerebrolysin is incompatible with solutions that contain lipids, and with solutions that change the pH of the medium (5.0-8.0).
Cerebrolysin is one of the safest drugs. The low molecular weight of its constituent neuropeptides excludes the possibility of anaphylactic reactions.
With caution, the drug is prescribed for allergic diathesis, large convulsive seizures.
Application in pediatrics
Cerebrolysin is used in all age groups of children, according to indications.
Features of the effect of the drug on the ability to drive vehicles or potentially dangerous mechanisms
The drug does not reduce the reaction and attention when driving vehicles and operating mechanisms.
The complex composition of Cerebrolysin, the active fraction of which consists of a balanced and stable mixture of biologically active oligopeptides with a total polyfunctional effect, does not allow for the usual pharmacokinetic analysis of individual components.
Until now, women who received Cerebrolysin during pregnancy did not have a negative effect on fetal development.
However, the use of the drug during pregnancy is strictly individual, as prescribed and monitored by the attending physician.
The drug is prescribed with caution in the first trimester of pregnancy and during lactation. During lactation, Cerebrolysin should be used only after a careful analysis of the ratio of the positive effect of treatment and the risk associated with its implementation.
– individual intolerance to the drug
– acute renal failure
– status epilepticus
– fever, sensation of heat (with rapid intravenous infusion)
– headache, dizziness
– loss of appetite, nausea, vomiting, dyspepsia, diarrhea, constipation
– allergic reactions: skin redness, itching and burning at the injection site
Mode of application
It is used only parenterally: in the form of intramuscular injections (up to 5 ml), and intravenous infusions (10-60 ml), it is recommended to enter only by slow intravenous infusions after dilution with the proposed standard solutions for infusion. The duration of the infusion is 15 to 60 minutes. Doses and duration of treatment depend on the nature and severity of the disease, as well as on the patient’s age. Perhaps the appointment of single doses, the value of which can reach 60 ml, but it is more preferable to conduct a course of treatment. The standard duration of treatment is 4 weeks (5 injections / infusions per week, preferably daily).
To increase the effectiveness of treatment, repeated courses can be carried out until positive treatment results are obtained. After the first course, the frequency of prescribing doses can be reduced to 2 or 3 times a week.
In Alzheimer’s disease, dementia syndrome of various origins: intravenous infusion of 20-30 ml in 100-200 ml of saline, for a course of treatment 20 infusions, 5 infusions per week (followed by a 2-day break) for 28 days. If necessary, the course of treatment is repeated after 3-6 months.
Acute conditions (ischemic stroke, acute and rehabilitation phase): in severe ischemic stroke, Cerebrolysin is prescribed as drip infusion in a daily dose of 20-30 ml in 100-250 ml of saline for 60-90 minutes. The duration of the course is 10-25 days.
For moderate ischemic stroke, the daily dose is 10-20 ml in 100-250 ml of saline for 60-90 minutes. The duration of the course of treatment is 10-25 days.
In the recovery period – 10 ml per day, intravenously, for 20-30 days.
Traumatic brain and spinal cord injury: intravenous infusion of 10-20 ml for 10-20 days. In the recovery period, intravenously, 5-10 ml, for 20-30 days.
With psychoorganic syndrome and endogenous depression: intravenous infusion of 5-30 ml, 5 infusions per week (followed by a 2-day break) for 20-25 days. If necessary, repeat the course of treatment after 6 months.
In neuropediatric practice (mental retardation in children, attention deficit disorders in children): the average daily dose is 0.1 – 0.2 ml / kg intramuscularly, daily. The duration of the course of treatment is 30 days, with a repetition of the course 2-3 times a year.
Ampoule 5 ml x 5 ampoules
sodium hydroxide, water for injection.
Shelf Life – 5 years